Skip to main content

Table 2 Pancreatic adenocarcinoma Incidence-based mortality rates (1973-2014)

From: Trends in pancreatic adenocarcinoma incidence and mortality in the United States in the last four decades; a SEER-based study

characteristic

Incidence-based mortality of pancreatic adenocarcinoma

Incidence-based mortality of adenocarcinoma of the head of pancreas

Incidence-based mortality of adenocarcinoma of the body and tail of pancreas

Cases, No (%)a,b

Rate (95% CI)c

Cases, No (%)a,b

Rate (95% CI) c

Cases, No (%)a,b

Rate (95% CI) c

Overall

63,426 (100)

6.52 (6.47 - 6.57)

31,609 (100)

3.26 (3.22 - 3.30)

12,859 (100)

1.32 (1.29 - 1.39)

Sex

 Male

32,771 (51.67)

7.73 (7.65 - 7.82)

15,975 (50.54)

3.79 (3.73 - 3.86)

6,903 (53.68)

1.61 (1.57 - 1.65)

 Female

30,655 (48.33)

5.58 (5.52 - 5.64)

15,634 (49.46)

2.84 (2.79 - 2.89)

5,956 (46.32)

1.09 (1.06 - 1.11)

Race

 White

51,742 (81.58)

6.36 (6.30 - 6.41)

25,815 (81.67)

3.18 (3.14 - 3.22)

10,289 (80.01)

1.26 (1.24 - 1.28)

 Black

7,309 (11.52)

9.42 (9.19 - 9.64)

3,736 (11.82)

4.84 (4.68 – 5.00)

1,557 (12.11)

1.99 (1.89 - 2.09)

 Othersd

4,313 (6.80)

5.34 (5.18 - 5.50)

2,030 (6.42)

2.52 (2.41 - 2.64)

997 (7.75)

1.22 (1.15 - 1.30)

 Unknowne

62 (0.10)

-

28 (0.09)

-

16 (0.13)

-

Age at death, y

 <60

13,432 (21.18)

1.59 (1.56 - 1.62)

6,358 (20.11)

0.75 (0.73 - 0.77)

2,869 (22.31)

0.34 (0.33 - 0.35)

 >60

49,994 (78.82)

31.45 (31.16 - 31.73)

25,251 (79.89)

15.93 (15.73 - 16.13)

9,990 (77.69)

6.25 (6.13 - 6.38)

Statef

 California

10,192 (16.07)

6.60 (6.47 - 6.73)

5,196 (16.44)

3.38 (3.29 - 3.47)

2,092 (16.27)

1.35 (1.29 - 1.41)

 Connecticut

10,146 (16.00)

6.90 (6.76 - 7.03)

4,991 (15.79)

3.39 (3.30 - 3.49)

2,077 (16.15)

1.41 (1.35 - 1.47)

 Georgia

4,635 (7.30)

6.57 (6.38 - 6.77)

2,362 (7.47)

3.38 (3.24 - 3.52)

1,012 (7.87)

1.41 (1.33 - 1.51)

 Hawaii

2,776 (4.38)

6.11 (5.88 - 6.34)

1,245 (3.94)

2.75 (2.60 - 2.91)

631 (4.91)

1.38 (1.27 - 1.49)

 Iowa

8,556 (13.49)

6.31 (6.17 - 6.44)

4,383 (13.87)

3.22 (3.12 - 3.32)

1,767 (13.74)

1.31 (1.25-1.37)

 Michigan

11,916 (18.79)

7.52 (7.38 - 7.66)

5,882 (18.61)

3.73 (3.63 - 3.82)

2,350 (18.27)

1.48 (1.42 -1.54)

 New Mexico

3,660 (5.77)

5.77 (5.59 - 5.97)

1,817 (5.75)

2.86 (2.73 - 3.00)

613 (4.77)

0.96 (0.88 - 1.04)

 Utah

2,948 (4.65)

4.99 (4.81 - 5.17)

1,471 (4.65)

2.51 (2.38 - 2.64)

591 (4.60)

0.99 (0.91 -1.07)

 Washington

8,597 (13.55)

6.25 (6.12 - 6.38)

4,262 (13.48)

3.11 (3.02 - 3.21)

1,726 (13.42)

1.25 (1.19-1.31)

Stage at diagnosisg

 Localized

4,656 (7.34)

0.49 (0.47 - 0.50)

3,250 (10.28)

0.34 (0.33 - 0.35)

610 (4.74)

0.06 (0.06 - 0.07)

 Regional

16,977 (26.77)

1.75 (1.72- 1.78)

12,083 (38.23)

1.25 (1.22 - 1.27)

1,878 (14.60)

0.19 (0.18 - 0.20)

 Distant

37,327 (58.85)

3.81 (3.78 - 3.85)

14,170 (44.83)

1.45 (1.42 - 1.47)

9,929 (77.21)

1.01 (0.99 - 1.03)

 Unstaged

4,466 (7.04)

0.47 (0.46-0.48)

2,106 (6.66)

0.22 (0.21-0.23)

442 (3.45)

0.05 (0.04-0.05)

  1. aCases included first primary tumors that matched the selection criteria, were microscopically confirmed, and were not identified only from autopsy records or death certificates
  2. bNo. (%) of deaths were based on cases diagnosed during 1973-2014
  3. cRates were calculated as number of deaths per 100 000 person-years and age adjusted to the 2000 US standard population
  4. dIncludes American Indian/Alaskan Native and Asian/Pacific Islander
  5. eRates for patients with unknown race could not be calculated, as ‘race’ is a population variable and must be known to calculate rates
  6. fRates were calculated between 1973-2014 for all states except Georgia; 1975-2014, and Washington; 1974-2014
  7. gUsing SEER historic stage A
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us